Headlines about GlycoMimetics (NASDAQ:GLYC) have been trending somewhat positive on Thursday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlycoMimetics earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.3521163386415 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of GlycoMimetics (NASDAQ:GLYC) opened at $22.49 on Thursday. GlycoMimetics has a 1 year low of $3.82 and a 1 year high of $25.20. The stock has a market cap of $772.26, a P/E ratio of -18.14 and a beta of 3.21.

GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. research analysts predict that GlycoMimetics will post -1.12 earnings per share for the current fiscal year.

A number of analysts recently issued reports on GLYC shares. Zacks Investment Research raised shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Monday, November 13th. Jefferies Group reissued a “buy” rating and set a $16.00 target price on shares of GlycoMimetics in a research report on Thursday, October 26th. Roth Capital started coverage on shares of GlycoMimetics in a research report on Monday, October 23rd. They set a “buy” rating and a $25.00 target price for the company. Stifel Nicolaus reissued a “buy” rating and set a $23.00 target price on shares of GlycoMimetics in a research report on Thursday, December 14th. Finally, SunTrust Banks increased their target price on shares of GlycoMimetics to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $21.00.

In other GlycoMimetics news, SVP Helen M. Thackray sold 2,000 shares of the stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $15.01, for a total value of $30,020.00. Following the completion of the sale, the senior vice president now owns 148,615 shares of the company’s stock, valued at $2,230,711.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 43.80% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “GlycoMimetics (GLYC) Earning Somewhat Favorable Media Coverage, Report Finds” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/glycomimetics-glyc-earning-somewhat-favorable-media-coverage-report-finds/1836249.html.

About GlycoMimetics

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Insider Buying and Selling by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.